- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
**Financial Performance:** Supreme Petrochem reported Q3 FY25 operating income of ₹1,405 Cr, with EBITDA at ₹116.70 Cr, reflecting a 5.5% increase in net profit after tax to ₹71 Cr and a PAT margin of 5.08%. Over 9 months, revenue reached ₹4,484 Cr with a PAT of ₹284 Cr, marking a 32% year-over-year increase and a PAT margin of 6.32%. Sales volumes rose by 21.1% in Q3 YOY, contributing to a 13.7% increase for the nine-month period. Despite positive revenue growth, EBITDA margins faced pressure due to declining prices of styrene monomers.
**Future Outlook and Growth Drivers:** Management expressed optimism regarding future strategies, emphasizing ongoing investments in capital projects, particularly the Mass ABS Project, expected to enhance production capacity. The commissioning of this project is slated for Q1 FY26. Plans for expansion at the Haryana plant are also underway, enhancing their product portfolio.
**Order Book and Operational Updates:** The Mass ABS facility is progressing with a mechanical completion targeted by March 2025. Initial discussions with customers regarding this new product line are promising, suggesting a robust market response upon launch.
**Analyst Q&A Insights:** Analysts sought clarifications about margin compressions and revenue projections. Management indicated that rising raw material costs initially hamper profitability but are hopeful for long-term improvement with ongoing capacity expansions. The company's expectations for export volumes remain cautious, while domestic growth projections are optimistic.
**Market or Regulatory Updates:** There were no specific regulatory updates affecting the company's operations. However, management highlighted ongoing discussions with various stakeholders to enhance product approval and market penetration.
**Strategic Focus Areas:** The emphasis was placed on enhancing operational efficiencies, particularly through the introduction of the Mass ABS product, which promises better product quality and margin expectations.
**Investor Insight:** The company exhibits solid financial health with a strong growth trajectory. Given the expansion plans and potential for higher margins from new product lines, this aligns well with a 'buy' stance for investors, while remaining alert to global price fluctuations and domestic competition that could impact margins.